Skip to main content
SpringerLink
Log in

Interaktionen zwischen Antiepileptika und Psychopharmaka

Interactions between antiepileptic drugs and psychotropic drugs

  • ÜBERSICHT
  • Published:
Zeitschrift für Epileptologie Aims and scope Submit manuscript

Abstract

Co-morbidity leads to an increasing number of drug prescriptions in the individual patient. Co-morbidity of epilepsy and psychiatric diseases is common. Therefore, possible interactions between antiepileptic drugs and those used in psychiatric diseases have to be considered. Pharmacokinetic interactions are common among drugs that are metabolized by cytochrome-P450 isoenzymes. It is crucial to know about possible drug interactions as they may lead both to impaired effectiveness and to uncontrolled toxicity of specific drugs.

Zusammenfassung

Begleiterkrankungen führen zur vermehrten Verordnung von Medikamentenkombinationen und damit zur Möglichkeit von Wechselwirkungen. Aufgrund einer hohen Komorbidität der Epilepsien mit psychischen Störungen kommt möglichen Interaktionen zwischen Antiepileptika und Psychopharmaka eine besondere Bedeutung zu. Die Möglichkeit pharmakokinetischer Interaktionen wird im Wesentlichen vom Stoffwechselweg der beteiligten Medikamente bestimmt. Dabei spielen die Isoenzyme des Cytochrom- P450 eine besonders große Rolle. Die Verordnung von Medikamenten, die nicht auf diesem Weg metabolisiert werden, kann das Risiko von Interaktionen verringern. Die Kenntnis möglicher Interaktionen ist unabdingbar, da diese einerseits über eine Beschleunigung des Abbaus zur verminderten Wirksamkeit eines Medikamentes, andererseits über eine Inhibition zu einem Anstieg des Serumspiegels und zu Intoxikationen führen können.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Literatur

  1. Andersen BB, Mikkelsen M, Vesterager A, Dam M, Kristensen HB, Pedersen B, Lund J, Mengel H (1991) No influence of the antidepressant paroxetine on carbamazepine, valproate and phenytoin. Epilepsy res 10:201–204

    Article  CAS  PubMed  Google Scholar 

  2. Behar D, Schaller J, Spreat S (1998) Extreme reduction of methylphenidate levels by carbamazepine. J Am Acad Child Adolesc Psychiatry 37:1128–1129

    CAS  PubMed  Google Scholar 

  3. Bergemann N, Frick A, Parzer P, Kopitz J (2004) Olanzapine plasma concentration, average daily dose, and interaction with co-medication in schizophrenic patients. Pharmacopsychiatry 37:63–68

    CAS  PubMed  Google Scholar 

  4. Berigan TR, Harazin J (1999) A sertraline/valproic acid drug interaction. Int J Psychiat Clin Pract 3:287–288

    Google Scholar 

  5. Bertoldo M (2002) Valproic acid and risperidone. J Am Acad Child Adolesc Psychiatry 41:632

    PubMed  Google Scholar 

  6. Bialer M, Doose DR, Murthy B, Curtin C, Wang SS, Twyman RE, Schwabe S (2004) Pharmacokinetic interactions of topiramate. Clin Pharmacokinet 43:763–780

    Article  CAS  PubMed  Google Scholar 

  7. Bocchetta A, Chillotti C, Severino G, Ardau R, Del Zompo M (1997) Carbamazepine augmentation in lithiumrefractory bipolar patients: A prospective study on long-term prophylactic effectiveness. J Clin Psychopharmacol 17:92–96

    Article  CAS  PubMed  Google Scholar 

  8. Bonnet P, Vandel S, Nezelof S, Sechter D, Bizouard P (1992) Carbamazepine, fluvoxamine: Is there a pharmacodynamic interaction? Therapie 47:165–167

    CAS  PubMed  Google Scholar 

  9. Braithwaite RA, Flanagan RJ (1975) Steady-state plasma nortriptyline concentrations in epileptic patients. Brit J Clin Pharmacol 2:469–471

    CAS  Google Scholar 

  10. Brøsen K, Kragh-Sørensen P (1993) Concomitant intake of nortriptyline and carbamazepine. Ther Drug Monit 15:258–260

    PubMed  Google Scholar 

  11. Brown CS, Wells BG, Cold JA, Froemming JH, Self TH, Jabbour JT (1990) Possible influence of carbamazepine on plasma imipramine concentrations in children with attention deficit hyperactivity disorder. J Clin Psychopharmacol 10:359–362

    CAS  PubMed  Google Scholar 

  12. Burstein AH, Horton RL, Dunn T, Alfaro RM, Piscitelli SC, Theodore W (2000) Lack of effect of St John’s wort on carbamazepine pharmacokinetics in healthy volunteers. Clinical Pharmacology & Therapeutics 68:605–612

    Article  CAS  Google Scholar 

  13. Chaudhry RP, Waters BGH (1983) Lithium and carbamazepine interaction: possible neurotoxicity. J Clin Psychiatry 44:30–31

    CAS  PubMed  Google Scholar 

  14. Chen C, Veronese L, Yin Y (2000) The effects of lamotrigine on the pharmacokinetics of lithium. Br J Clin Pharmacol 50:193–195

    CAS  PubMed  Google Scholar 

  15. Chengappa KN, Gershon S, Levine J (2001) The evolving role of topiramate among other mood stabilizers in the management of bipolar disorder. Bipolar Disord 3:215–232

    CAS  PubMed  Google Scholar 

  16. Conca A, Beraus W, König P, Waschgler R (2000) A case of pharmacokinetic interference in comedication of clozapine and valproic acid. Pharmacopsychiatry 33:234–235

    Article  CAS  PubMed  Google Scholar 

  17. Costello LE, Suppes T (1995) A clinically significant interaction between clozapine and valproate. J Clin Psychopharmacol 15:139–141

    Article  CAS  PubMed  Google Scholar 

  18. Darley J (1994) Interaction between phenytoin and fluoxetine. Seizure 3:151–152

    Article  CAS  PubMed  Google Scholar 

  19. De Toledo JC, Haddad H, Ramsay RE (1997) Status epilepticus associated with the combination of valproic acid and clomipramine. Ther Drug Monit 19:71–73

    CAS  Google Scholar 

  20. Doose DR, Kohl KA, Desai-Krieger D, Natarajan J, van Kammen DP (1999) No clinical significant effect of topiramate on haloperidol plasma concentration. Eur Neuropsychopharmacol 9:S357

    Article  Google Scholar 

  21. Dorn JM (1986) A case of phenytoin toxicity possibly precipitated by trazodone. J Clin Psychiatry 47:89–90

    CAS  PubMed  Google Scholar 

  22. Dursun SM, Mathew VM, Reveley MA (1993) Toxic serotonin syndrome after fluoxetine plus catbamazepine. Lancet 342:442–443

    Article  CAS  PubMed  Google Scholar 

  23. Eap CB, Yasui N, Kaneko S, Baumann P, Powell K, Otani K (1999) Effects of carbamazepine coadministrationon plasma concentrations of of the enantiomers of mianserin and of its metabolites. Ther Drug Monit 21:166–170

    Article  CAS  PubMed  Google Scholar 

  24. Ereshefsky L (1996) Drug-drug interactions involving antiedepressants: focus on venlafaxine. Journal clin psychopharmacol 16:37S–50S

    CAS  Google Scholar 

  25. Facciolá G, Avenoso A, Spina E, Perucca E (1998) Inducing effect of Phenobarbital on clozapine metabolism in patients with chronic schizophrenia. Ther Drug Monit 20:628–630

    PubMed  Google Scholar 

  26. Facciolá G, Avenoso A, Scordo MG, Madia AG, Ventimiglia A, Perucca E, Spina E (1999) Small effects of valproic acid on the plasma concentrations of clozapine and its major metabolites in patients with schizophrenic or affective disorders. Ther Drug Monit 21:341–345

    PubMed  Google Scholar 

  27. Fehr C, Gründer G, Hiemke C, Dahmen N (2000) Increase in serum clomipramine concentrations caused by valproic acid. J Clin Psychopharmacol 20:493–494

    Article  CAS  PubMed  Google Scholar 

  28. Finley P, Warner D (1994) Potential impact of valproic acid therapy on clozapine disposition. Biol Psychiatry 36:487–488

    Article  CAS  Google Scholar 

  29. Fitzgerald BJ, Okos AJ (2002) Elevation of Carbamazepine-10,11-Epoxid by Quetiapine. Pharmacotherapy 22:1500–1503

    PubMed  Google Scholar 

  30. Forrest FM, Forrest IS, Serra MT (1970) Modification of chlorpromazine metabolism by some other drugs frequently administered to psychiatric patients. Biological Psychiatry 2:53–58

    CAS  PubMed  Google Scholar 

  31. French JA, Gidal BE (2000) Antiepileptic drug interactions. Epilepsia 41, Suppl. 8:S30–S36

    Article  CAS  PubMed  Google Scholar 

  32. Fritze J, Unsorg B, Lanczik M (1991) Interaction between carbamazepine and fluvoxamine. Acta Psychiatrica Scandinavica 84:583–584

    CAS  PubMed  Google Scholar 

  33. Frye MA, Kimbrell TA, Dunn RT, Piscitelli S, Grothe D, Vanderham E, Cora-Locatelli G, Post RM, Ketter TA (1998) Gabapentin does not alter single-dose lithium pharmacokinetics. J Clin Psychopharmacol 18:461–464

    Article  CAS  PubMed  Google Scholar 

  34. Gaitatzis A, Carroll K, Majeed A, W Sander J (2004) The epidemiology of the comorbidity of epilepsy in the general population. Epilepsia 45:1613–1622

    Article  PubMed  Google Scholar 

  35. Gay PE, Madsen JA (1983) Interaction between phenobarbital and thioridazine. Neurology 33:1631–1632

    CAS  PubMed  Google Scholar 

  36. Gex-Fabri M, Balant-Gorgia AE, Balant LP (2003) Therapeutic drug monitoring of olanzapine: the combined effect of age, gender, smoking, and comedication. Ther Drug Monit 25:46–53

    Google Scholar 

  37. Granneman GR, Schneck DW, Cavanaugh JH, Witt GF (1996) Pharmacokinetic interactions and side effects resulting from concomitant administration of lithium and divalproex sodium. Journal Clin Psychiatry 57:204–206

    CAS  Google Scholar 

  38. Greb WH, Buscher G, Dierdorf HD, Köster FE, Wolf D, Mellows G (1989) The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine. Acta Psychiatr Scand 80 Suppl. 350:95–98

    Google Scholar 

  39. Grimsley SR, Jann MW, Carter JG, D’Mello AP, D’Souza MJ (1991) Increased carbamazepine plasma concentrations after fluoxetine coadministration. Clin Pharmacol Ther 50:10–15

    CAS  PubMed  Google Scholar 

  40. Gross-Tsur V (1999) Carbamazepine and methylphenidate. Journal of the American Academy of Child & Adolescent Psychiatry 38:637

    CAS  Google Scholar 

  41. Haidukewych D, Rodin EA (1985) Effect of phenothiazines on serum antiepileptic drug concentrations in psychiatric patients with seizure disorder. Ther Drug Monit 7:401–404

    CAS  PubMed  Google Scholar 

  42. Haselberger MB, Freedman LS, Tolbert S (1997) Elevated serum Phenytoin concentrations associated with coadministration of sertraline. J Clin Psychopharmacol 17:107–109

    Article  CAS  PubMed  Google Scholar 

  43. Hesslinger B, Normann C, Langosch JM, Klose P, Berger M, Walden J (1999) Effects of carbamazepine and valproate on haloperidol plasma levels and on psychopathologic outcome in schizophrenic patients. J Clin Psychopharmacol 19:310–315

    Article  CAS  PubMed  Google Scholar 

  44. Houghton GW, Richens A (1975) Inhibition of phenytoin metabolism by other drugs used in epilepsy. Int J Clin Pharmacol 12:210–216

    CAS  Google Scholar 

  45. Ishizaki T, Chiba K, Saito M, Kobayashi K, Iizuka R (1984) The effects of neuroleptics (haloperidol and chlorpromazine) on the pharmacokinetics of valproic acid in schizophrenic patients. J Clin Psychopharmacol 4:254–261

    CAS  PubMed  Google Scholar 

  46. Iwahashi K, Miyatake R, Suwaki H, Hosokawa K, Ichikawa Y (1995) The drug-drug interaction effects of haloperidol on plasma carbamazepine levels. Clin Neuropharmacol 18:233–236

    CAS  PubMed  Google Scholar 

  47. Jalil P (1992) Toxic reaction following the combined administration of fluoxetine and phenytoin: two case reports. JNNP 55:412–413

    CAS  Google Scholar 

  48. Jerling M, Lindström L, Bondesson U, Bertilsson L (1994) Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: evidence from a therapeutic drug monitoring service. Ther Drug Monit 16:368–374

    CAS  PubMed  Google Scholar 

  49. Jerling M, Bertilsson L, Sjöqvist F (1994) The use of therapeutic drug monitoring data to document kinetic drug interactions: an example with amitriptyline and nortriptyline. Ther Drug Monit 16:1–12

    CAS  PubMed  Google Scholar 

  50. Joblin M, Ghose K (1994) Possible interaction of sertraline with carbamazepine. New Zealand Medical Journal 107:43

    CAS  PubMed  Google Scholar 

  51. Joffe T, Post RM, Uhde TW (1985) Lack of pharmacokinetic interaction of carbamazepine with tranylcypramine. Archives of General Psychiatry 42:738

    CAS  PubMed  Google Scholar 

  52. Joseph AB, Wroblewsky BA (1993) Potentially toxic serum concentrations of desipramine after discontinuation of valproic acid. Brain Injury 7:463–465

    CAS  PubMed  Google Scholar 

  53. Kanter GL, Yerewanian Bi, Ciccone JR (1984) Case report of a possible interaction between neuroleptics and carbamazepine. Am J Psychiatry 141:1101–1102

    CAS  PubMed  Google Scholar 

  54. Kaufmann, KR Gerner, R (1998) Case report: Lamotrigine toxicity secondary to sertraline. Seizure 7:163–165

    Google Scholar 

  55. Ketter TA, Jenkins JB, Schroeder DH, Pazzaglia PJ, Marangell LB, George MS, Callahan AM, Hinton ML, Chao J, Post RM (1995) Carbamazepine but not valproate induces bupropion metabolism. J Clin Psychopharmacol 15:327–333

    CAS  PubMed  Google Scholar 

  56. Ketter TA, Post RM, Parekh PI, Worthington K (1995) Addition of monoamine oxidase inhibitors to carbamazepine: preliminary evidence of safety and efficacy in treatment-resistant depression. Journal of Clinical Psychiatry 56:471–475

    CAS  PubMed  Google Scholar 

  57. Khan A, Shad MU, Preskorn SH (2000) Lack of sertraline efficacy probably due to an interaction with carbamazepine. J clin psychiatry 61:526–527

    CAS  PubMed  Google Scholar 

  58. Kossen M, Selten JP, Kahn RS (2001) Elevated clozapine plasma level with lamotrigine. Am J Psychiatry 158:1930

    Article  CAS  PubMed  Google Scholar 

  59. Langbehn DR, Alexander B (2000) Increased risk of side effects in psychiatric patients treated with clozapine and carbamazepine: a reanalysis. Pharmacopsychiatry 33:196

    CAS  PubMed  Google Scholar 

  60. Leinonen E, Lillsunde P, Laukkanen V, Ylitalo P (1991) Effects of carbamazepine on serum antidepressant concentrations in psychiatric patients. J Clin Psychopharmacol 11:313–318

    CAS  PubMed  Google Scholar 

  61. Leinonen E, Lepola U, Koponen H (1996) Substituting carbamazepine with oxcarbazepine increases citalopram levels. A report on two cases. Pharmacopsychiatry 29:156–158

    CAS  PubMed  Google Scholar 

  62. Licht RW, Olesen OV, Friis P, Laustsen T (2000) Olanzapine serum concentrations lowered by concomitant treatment with carbamazepine. J Clin Psychopharmacol 20:110–112

    Article  CAS  PubMed  Google Scholar 

  63. Linnet K, Olesen OV (2002) Free and glucuronidated olanzapine serum concentrations in psychiatric patients: influence of carbamazepine comedication. Ther Drug Monit 24:512–517

    Article  CAS  PubMed  Google Scholar 

  64. Linnoila M, Viukari M, Vaisanen K, Auvinen J (1980) Effect of anticonvulsants on plasma haloperidol and thioridazine levels. American Journal of Psychiatry 137:819–821

    CAS  PubMed  Google Scholar 

  65. Loga S, Curry S, Lader M (1975) Interactions of orphenadrine and phenobarbitone with chlorpromazine: plasma concentrations and effects in man. British Journal of Clinical Pharmacology 2:197–208

    CAS  PubMed  Google Scholar 

  66. Lucas RA, Gilfillan DJ, Bergstrom RF (1998) A pharmacokinetic interaction between carbamazepine and olanzapine: observations on possible mechanism. Eur J Clin Pharmacol 54:639–643

    Article  CAS  PubMed  Google Scholar 

  67. Lucena MI, Blanco E, Corrales MA, Berthier ML (1998) Interaction of fluoxetine and valproic acid. Am J Psychiatry 155:575

    CAS  PubMed  Google Scholar 

  68. Lydiard RB, White D, Harvey B, Taylor A (1987) Lack of pharmacokinetic interaction between tranylcypromine and carbamazepine. J Clin Psychopharmacol 7:360

    CAS  PubMed  Google Scholar 

  69. Madeb R, Hirschmann S, Kurs R, Turkie A, Modai I (2002) Combined clozapine and valproic acid treatment-induced agranulocytosis. Eur Psychiatry 17:238–239

    Article  CAS  PubMed  Google Scholar 

  70. Mamiya K, Ieiri I, Shimamoto J, Yukawa E, Imai J, Ninomiya H, Yamada H, Otsubo K, Higuchi S, Tashiro N (1998) The effects of genetic polymorphism of CYP2C9 and CYP2C19 on Phenytoin metabolism in japanese adult patients with epilepsy: studies in stereoselective hydroxylation and population pharmacokinetics. Epilepsia 39:1317–1323

    Article  CAS  PubMed  Google Scholar 

  71. Mamiya K, Kojima K, Yukawa E, Higuchi S, Ieiri I, Ninomiya H, Tashiro N (2001) Phenytoin intoxication induced by fluvoxamine. Ther Drug Monit 23:75–77

    CAS  PubMed  Google Scholar 

  72. Markowitz JS, Patrick KS (2001) Pharmacokinetic and pharmacodynamic drug interactions in the treatment of attention deficit hyperactivity disorder. Clin Pharmacokinet 40:752–772

    Article  Google Scholar 

  73. Markowitz JS, Donovan JI, DeVane CL, Taylor RM, Ruan Y, Wang JS, Chavin KD (2003) Effect of St John’s wort on drug metabolism by induction of cytochrome P4503A4 enzyme. JAMA 290:1500–1504

    CAS  PubMed  Google Scholar 

  74. Martinelli V, Bocchetta A, Palmas AM, Del Zompo M (1993) An interaction between carbamazepine and fluvoxamine. British Journal of Clinical Pharmacology 36:615–616

    CAS  PubMed  Google Scholar 

  75. Mayan H, Golubev N, Dinour D, Farvel Z (2001) Lithium intoxication due to carbamazepine-induced renal failure. Ann Pharmacother 35:560–562

    Article  CAS  PubMed  Google Scholar 

  76. Miceli JJ, Anziano RJ, Robarge L, Hansen RA, Laurent A (2000) The effect of carbamazepine on the steadystate pharmacokinetics of ziprasidone in healthy volunteers. Brit J Clin Pharmacol 49:65S–70S

    CAS  Google Scholar 

  77. Miller DD (1991) Effect of Phenytoin on plasma clozapine concentrations in two patients. J Clin Psychiatry 52:23–25

    CAS  PubMed  Google Scholar 

  78. Møller SE, Larsen F, Khan AZ, Rolan PE(2001) Lack of effect of citalopram on the steady-state pharmacokinetics of carbamazepine in healthy male subjects. J Clin Psychopharmacol 21:493–499

    PubMed  Google Scholar 

  79. Mula M, Monaco F (2002) Carbamazepine-risperidone interactions in patients with epilepsy. Clin Neuropharmacol 25:97–100

    CAS  PubMed  Google Scholar 

  80. Muscatello RM, Pacetti M, Cacciola M, La Torre D, Zoccali R, D’Arrigo C, Migliardi G, Spina E (2005) Plasma Concentrations of Risperidone and Olanzapine during Coadministration with Oxcarbazepine. Epilepsia 46:771–774

    CAS  Google Scholar 

  81. Nawishy S, Hathway N, Turner P (1981) Interactions of anticonvulsant drugs with mianserine and nomifensine. Lancet 8251:871–872

    Google Scholar 

  82. Normann C, Hesslinger B, Bauer J, Berger M, Walden J (1998) Die Bedeutung des hepatischen Cytochrom-P450-Systems für die Psychopharmakologie. Nervenarzt 69:944–955

    Article  CAS  PubMed  Google Scholar 

  83. Normann C, Hummel B, Schärer LO, Hörn M, Grunze H, Walden J (2002) Lamotrigine as adjunct therapy to paroxetine in acute depression: a placebo-controlled, double-blind study. Journal of Clinical Psychiatry 63:337–344

    CAS  PubMed  Google Scholar 

  84. Odishaw J, Chen C (2000) Effects of steady-state bupropion on the pharmacokinetics of lamotrigine in healthy subjects. Pharmacotherapy 20:1448–1453

    CAS  PubMed  Google Scholar 

  85. Odou P, Geronimi-Ferret D, Degen P, Robert H (1996) Viloxazine-carbamazépine: double interaction dangereuse? A propos d’un cas. Journal de pharmacie clinique 15:157–160

    Google Scholar 

  86. Ono S, Mihara K, Suzuki A, Kondo T, Yasuo-Furukori N, Furukori H, de Vries R, Kaneko S (2002) Significant pharmacokinetic interaction between risperidone and carbamazepine: its relationship with CYP2D6 genotypes. Psychopharmacology 162:50–54

    Article  CAS  PubMed  Google Scholar 

  87. Otani K, Ishida M, Yasui N, Kondo T, Mihara K, Suzuki A, Furukori H, Kaneko S, Inoue Y (1997) Interaction between carbamazepine and bromperidol. Eur J Clin Pharmacol 52:219–222

    Article  CAS  PubMed  Google Scholar 

  88. Otani K, Ishida M, Kaneko S, Mihara K, Ohkubo T, Osanai T, Sugawara K (1996) Effects of carbamazepine coadministration on plasma concentrations of trazodone and its active metabolite, m-Chlorophenylpiperazine. Ther Drug Monit 18:164–167

    Article  CAS  PubMed  Google Scholar 

  89. Patsalos PN (2000) Antiepileptic drug pharmacogenetics. Ther Drug Monit 22:127–130

    Article  CAS  PubMed  Google Scholar 

  90. Patsalos PN, Froscher W, Pisani F, van Rijn CM (2002) The importance of drug interactions in epilepsy therapy. Epilepsia 43:365–385

    Article  CAS  PubMed  Google Scholar 

  91. Patsalos PN, Perucca E (2003) Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs. Lancet Neurol 2:347–356

    CAS  PubMed  Google Scholar 

  92. Pearson HJ (1990) Interaction of fluoxetine with carbamazepine. J Clin Psychiatry 51:126

    CAS  PubMed  Google Scholar 

  93. Perucca E, Richens A (1977) Interaction between phenytoin and imipramine. British J Clin Pharmacol 4:485–486

    CAS  Google Scholar 

  94. Pies R (2002) Combining lithium and anticonvulsants in bipolar disorder: a review. Annals of Clinical Psychiatry 14:223–232

    Article  PubMed  Google Scholar 

  95. Pihlsgård M, Eliasson E (2002) Significant reduction of sertralin plasma levels by carbamazepine and phenytoin. Eur J Clin Pharmacol 57:915–916

    PubMed  Google Scholar 

  96. Pinninti NR, Zelinski G (2002) Does topiramate elevate serum lithium levels? J Clin Psychopharmacol 22:340

    Article  PubMed  Google Scholar 

  97. Pisani F, Narbone MC, Fazio A, Crisafulli P, Primerano G, Amendola D’Agostino A, Oteri G, Di Perri R (1984) Effect of viloxazine on serum carbamazepine levels in epileptic patients. Epilepsia 25:482–485

    CAS  PubMed  Google Scholar 

  98. Pisani F, Fazio A, Oteri G, Perucca E, Russo M, Trio R, Pisani B, Di Perri R (1986) Carbamazepine-viloxazine interaction in patients with epilepsy. JNNP 49:1142–1145

    CAS  Google Scholar 

  99. Pisani F, Fazio A, Artesi C, Russo M, Trio R, Oteri G, Perucca E, Di Perri R(1992) Elevation of plasma phenytoin by viloxazine in epileptic patients. JNNP 55:126–127

    CAS  Google Scholar 

  100. Pisani F, Fazio A, Oteri G, Artesi C, Xiao B, Perucca E, Di Perri R(1994) Effects of the antidepressant drug viloxazine on oxcarbazepine and its hydroxylated metabolites in patients with epilepsy. Acta Neurol Scand 90:130–132

    CAS  PubMed  Google Scholar 

  101. Popli AP, Tanquary J, Lamparella V, Masand PS (1995) Bupropion and anticonvulsant drug interactions. Ann Clin Psychiatry 7:99–101

    CAS  PubMed  Google Scholar 

  102. Preskorn SH, Alderman J, Greenblatt DJ, Horst WD (1997) Sertraline does not inhibit cytochrome P450 3Amediated drug metabolismin vivo. Psychopharmacology Bulletin 33:659–665

    CAS  PubMed  Google Scholar 

  103. Pupeschi G, Agenet C, Levron JC, Barges-Bertocchio MH (1994) Do enzyme inducers modify haloperidol decanoate rate of release? Prog Neuro-Psychopharmacol & Biol Psychiat 18:1323–1332

    CAS  Google Scholar 

  104. Raitasuo V, Lehtovaara R, Huttunen MO (1993) Carbamazepine and plasma levels of clozapine. Am J Psychiatry 150:169

    CAS  PubMed  Google Scholar 

  105. Raitasao V, Lehtovaara R, Huttunen MO (1994) Effect of switching carbamazepine to oxcarbazepine on the plasma levels of neuroleptics. A case report. Psychopharmacology 116:115–116

    Article  CAS  PubMed  Google Scholar 

  106. Ranjan S, Jagadheesan K, Nizamie SH (2002) Cerebellar ataxia with intravenous valproate and haloperidol. Australian and New Zealand Journal of Psychiatry 36:268

    Article  PubMed  Google Scholar 

  107. Rapeport WG, Williams SA, Muirhead DC, Dewland PM, Tanner T, Wesnes K (1996) Absence of a sertraline-mediated effect on the pharmacokinetics and pharmacodynamics of carbamazepine. J Clin Psychiatry 57; Suppl. 1:20–23

    CAS  PubMed  Google Scholar 

  108. Rapeport WG, Muirhead DC, Williams SA, Cross M, Wesnes K (1996) Absence of effect of sertraline on the pharmacokinetics and pharmacodynamics of phenytoin. J Clin Psychiatry 57:24–28

    CAS  PubMed  Google Scholar 

  109. Reimers A, Skogvoll E, Kutschera J, Spigset O (2005) Drug interactions between lamotrigine and psychoactive drugs: Evidence from a therapeutic drug monitoring service. J Clin Psychopharmacol 25:342–348

    Article  CAS  PubMed  Google Scholar 

  110. Sánchez Romero A, Garca Delgado R, Flores Pea M (1999) Interaction between trazodone and carbamazepine. Annals of Pharmacotherapy 33:1370

    Google Scholar 

  111. Sands CD, Robinson JD, Salem RB, Stewart RB, Muniz C (1987) Effect of thioridazine on phenytoin serum concentration: a retrospective study. Drug intelligence and clinical pharmacy 21:267–272

    CAS  Google Scholar 

  112. Shad MU (2004) A complex interaction between clozapine and phenytoin. Journal of Pharmacy Technology 20:280–282

    Google Scholar 

  113. Shukla S, Godwin CD, Long LEB, Miller MG (1984) Lithium-Carbamazepine neurotoxicity and risk factors. Am J Psychiatry 141:1604–1606

    CAS  PubMed  Google Scholar 

  114. Sitsen JMA, Maris FA, Timmer CJ (2001) Drug-drug interaction studies with mirtazapine and carbamazepine in healthy male subjects. Eur J Drug Metab Pharmacokinet 26:109–121

    CAS  PubMed  Google Scholar 

  115. Sovner R, Davis JM (1991) A possible interaction between fluoxetine and valproic acid. J Clin Psychopharmacol 11:389

    CAS  PubMed  Google Scholar 

  116. Spaans E, van den Heuvel MW, Schnabel PG, Peters PAM, Chin-Kon-Sung UG, Colbers EPH, Sitsen JMA (2002) Concomitant use of mirtazapine and phenytoin: A drug-drug interaction study in healthy male subjects. Eur J Clin Pharmacol 58:423–429

    CAS  PubMed  Google Scholar 

  117. Spina E, Amendola D’Agostino AM, Ioculano MP, Oteri G, Fazio A, Pisani F (1990) No effect of thioridazine on plasma concentrations of carbamazepine and its active metabolite carbamazepine-10,11-epoxide. Ther Drug Monit 12:511–513

    CAS  PubMed  Google Scholar 

  118. Spina E, Avenoso A, Pollicino AM, Caputi AP, Fazio A, Pisani F (1993) Carbamazepine coadministration with fluoxetine or fluvoxamine. Ther Drug Monit 15:247–250

    CAS  PubMed  Google Scholar 

  119. Spina E, Avenoso A, Campo GM, Caputi AP, Perucca E (1996) Phenobarbital induces the 2-hydroxylation of desipramine. Ther Drug Monit 18:60–64

    Article  CAS  PubMed  Google Scholar 

  120. Spina E, Avenoso A, Facciolá G, Salemi M, Scordo MG, Giacobello T, Madia AG, Perucca E (2000) Plasma concentrations of risperidone and 9-hydroyrisperidone: Effect of comedication with carbamazepine or valproate. Ther Drug Monit 22:481–485

    Article  CAS  PubMed  Google Scholar 

  121. Spina E, Scordo MG, Avenoso A, Perucca E (2001) Adverse drug interaction between Risperidone and Carbamazepine in a patient with chronic schizophrenia and deficient CYP2D6 activity. J Clin Psychopharmacol 21:108–109

    Article  CAS  PubMed  Google Scholar 

  122. Spina E, Perucca E (2002) Clinical significance of pharmacokinetic interactions between antiepileptic and psychotropic drugs. Epilepsia 43, Suppl 2:37–44

    Article  PubMed  Google Scholar 

  123. Spina E, Scordo MG, D’Arrigo C (2003) Metabolic drug interactions with new psychotropic drugs. Fundam Clin Pharmacol 17:517–538

    Article  CAS  PubMed  Google Scholar 

  124. Steinacher L, Vandel P, Zullino DF, Eap CB, Brawand-Amey M, Baumann P (2002) Carbamazepine augmentation in depressive patients non-responding to citalopram: a pharmacokinetic and clinical pilot study. European Neuropsychopharmacology 12:255–260

    Article  CAS  PubMed  Google Scholar 

  125. Szymura-Oleksiak J, Wyska E, Wasieczko A (2001) Pharmacokinetic interaction between imipramine and carbamazepine in patients with major depression. Psychopharmacology 154:38–42

    Article  CAS  PubMed  Google Scholar 

  126. Takahashi H, Yoshida K, Higuchi H, Shimizo T (2001) Development of parkinsonian symptoms after discontinuation of carbamazepine in patients concurrently treated with risperidone: two case reports. Clin Neuropharmacol 24:358–360

    CAS  PubMed  Google Scholar 

  127. Taylor D (1997) Pharmacokinetic interactions involving clozapine. Brit J Psychiatry 171:109–112

    CAS  Google Scholar 

  128. Tiihonen J, Vartiainen H, Hakola P (1995) Carbamazepine-induced changes in plasma levels of neuroleptics. Pharmacopsychiatry 28:26–28

    CAS  PubMed  Google Scholar 

  129. Turnheim K (2004) Arzneimittelwechselwirkungen mit Antiepileptika. Wien Klin Wochenschr 116:112–118

    CAS  PubMed  Google Scholar 

  130. van Wattum PJ (2001) Valproic acid and risperidone. J Am Acad Child Adolesc Psychiatry 40:866–867

    CAS  PubMed  Google Scholar 

  131. Vercueil L, Adriantseheno LM, Hirsch E (1998) Surdosage en carbamazepine aprs administration d’un comprimé de sertraline: relation au syndrome sérotonergique? Thérapie 53:502–504

    CAS  PubMed  Google Scholar 

  132. Vincent FM (1980) Phenothizine-induced Phenytoin intoxication. Annals of Internal Medicine 93:56–57

    CAS  PubMed  Google Scholar 

  133. Vitiello B (2001) Valproic acid and risperidone. J Am Acad Child Adolesc Psychiatry 40:867

    Google Scholar 

  134. Wiklander B, Danjou P, Rolan P, Tamin SK, Toon S (1995) Evaluation of the potential pharmacokinetic interaction of venlafaxine and carbamazepine. European Neuropsychopharmacology 5:310–311

    Article  Google Scholar 

  135. Wirshing WC, Ames D, Bisheff S, Pierre JM, Mendoza A, Sun A (1997) Hepatic encephalopathy associated with combined clozapine and divalproex sodium treatment. J Clin Psychopharmacol 17:120–121

    Article  CAS  PubMed  Google Scholar 

  136. Wong SL, Cavanaugh J, Shi H, Awni WM, Grannemann GR (1996) Effects of divalproex sodium on amitriptyline and nortriptyline pharmacokinetics. Clinical Pharmacology & Therapeutics 60:48–53

    Article  CAS  Google Scholar 

  137. Wong YWJ, Yeh C, Thyrum PT (2000) The effects of concomitant phenytoin administration on the steady-state pharmacokinetics of quetiapine. J Clin Psychopharmacol 21:89–93

    Google Scholar 

  138. Woods DJ, Coulter DM, Pillans P (1994) Interaction of phenytoin and fluoxetine. New Zealand Medical Journal 107:19

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Abt. für Allgemeine Epileptologie, Ev. Krankenhaus Bielefeld, Epilepsiezentrum Bethel (Kliniken), Maraweg 21, 33617, Bielefeld

    Christian Brandt &  Bernd Pohlmann-Eden

Authors
  1. Christian Brandt
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bernd Pohlmann-Eden
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Christian Brandt.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Brandt, C., Pohlmann-Eden, B. Interaktionen zwischen Antiepileptika und Psychopharmaka. Z. Epileptol. 19, 95–108 (2006). https://doi.org/10.1007/s10309-006-0185-1

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10309-006-0185-1

Key words

Schlüsselwörter

Search

Navigation